Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

Jaypirca gains expanded approval; allograft approved to restore peripheral nerve function; baxdrostat to be reviewed as an add-on treatment for hypertension; treatment for a genetic eye disorder that ...

The new recommendation allows parents to make the decision on when or if their child will receive the hepatitis B vaccine.

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

HealthDay News — Adjunct corticosteroids probably reduce short-term mortality in adults with severe pneumonia or acute respiratory distress syndrome (ARDS), according to a review published online ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

HealthDay News — For adult patients with hereditary hemorrhagic telangiectasia (HHT), a new, allosteric, selective activin receptor-like kinase 1 inhibitor, oral engasertib, is safe and is associated ...

Pazdur reportedly questioned whether a new FDA program called the Commissioner’s National Priority Voucher, designed to speed reviews for drugs tied to national priorities, was transparent or even ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

HealthDay News — Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the Food and Drug Administration (FDA) warns that some sensors from Abbott may ...

Higher risk for overdose seen with lower adherence for 12 months, discontinuation in three to nine months, discontinuation in less than three months ...